The DOI matches its Crossref record; 288 of the 288 references it cites were found in a registry or an index.
Cell cycle proteins as promising targets in cancer therapy
Open accessAbstract
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant activity of various cell cycle proteins. Therefore, cell cycle regulators are considered attractive targets in cancer therapy. Intriguingly, animal models demonstrate that some of these proteins are not essential for proliferation of non-transformed cells and development of most tissues. By contrast, many cancers are uniquely dependent on these proteins and hence are selectively sensitive to their inhibition. After decades of research on the physiological functions of cell cycle proteins and their relevance for cancer, this knowledge recently translated into the first approved cancer therapeutic targeting of a direct regulator of the cell cycle. In this Review, we focus on proteins that directly regulate cell cycle progression (such as cyclin-dependent kinases (CDKs)), as well as checkpoint kinases, Aurora kinases and Polo-like kinases (PLKs). We discuss the role of cell cycle proteins in cancer, the rationale for targeting them in cancer treatment and results of clinical trials, as well as the future therapeutic potential of various cell cycle inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–288 of 288
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas
Ma, Y., Fiering, S., Black, C. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606537104 · Cited by 81
Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Davies, K. D., Cable, P. L., Garrus, J. E., Sullivan, F. X., von Carlowitz, I., Huérou, Y. L., Wallace, E. M., Woessner, R. D., & Gross, S. D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17673 · Cited by 81
Cooperation between Cyclin E and p27Kip1 in Pituitary Tumorigenesis
Roussel-Gervais, A., Bilodeau, S., Vallette-Kasic, S., Berthelet, F., Lacroix, A., Figarella‐Branger, D., Brue, T. C., & Drouin, J. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0091 · Cited by 79
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E., Riffell, J. L., Bardelli, A., Torrance, C. J., Lord, C. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149099 · Cited by 78
Rodríguez‐Puebla, M. L., de Marval, P. L. M., LaCava, M., Moons, D. S., Kiyokawa, H., & Conti, C. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64196-x · Cited by 76
Vaughn, D. J., Hwang, W., Lal, P., Rosen, M. A., Gallagher, M., & O'Dwyer, P. J. (2015) · Cancer · doi:10.1002/cncr.29213 · Cited by 74
Silverman, L. R., Greenberg, P. L., Raza, A., Olnes, M. J., Holland, J. F., Reddy, P. E., Maniar, M. L., & Wilhelm, F. E. (2014) · Hematological Oncology · doi:10.1002/hon.2137 · Cited by 71
Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice
Yao, Y., Slosberg, E. D., Wang, L., Hibshoosh, H. H., Zhang, Y., Xing, W.-Q., Santella, R. M., & Weinstein, I. B. (1999) · Oncogene · doi:10.1038/sj.onc.1202908 · Cited by 71
Deregulated CDC25A Expression Promotes Mammary Tumorigenesis with Genomic Instability
Ray, D., Terao, Y., Fuhrken, P. G., Ma, Z.-Q., DeMayo, F. J., Christov, K. T., Heerema, N. A., Franks, R. R., Tsai, S. Y., Papoutsakis, E. T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3927 · Cited by 69
Collaboration of Brca1 and Chk2 in tumorigenesisPreprint
McPherson, J. P., Lemmers, B., Hirao, A., Hakem, A., Abraham, J., Migon, E., Matysiak‐Zablocki, E., Tamblyn, L., Sanchez-Sweatman, O. H., Khokha, R., et al. (2004) · Genes & Development · doi:10.1101/gad.1192704 · Cited by 68
Shapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Kulanthaivel, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2500 · Cited by 67
Aurora-A gene is frequently amplified in basal-like breast cancer
Staff, S. M. (2009) · Oncology Reports · doi:10.3892/or_00000637 · Cited by 67
Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma
Xie, Y., Wei, R.-R., Huang, G., Zhang, M.-Y., Yuan, Y., & Wang, H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0844-4 · Cited by 66
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Dolman, M. E. M., Poon, E., Ebus, M. E., den Hartog, I. J. M., van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K. R., Sparidans, R. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0313 · Cited by 66
Albanese, C., Alzani, R., Amboldi, N., Avanzi, N. R., Ballinari, D., Brasca, M. G., Festuccia, C., Fiorentini, F., Locatelli, G., Pastori, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0190 · Cited by 66
Hu, C., Dadon, T., Chenna, V., Yabuuchi, S., Bannerji, R., Booher, R., Strack, P. R., Azad, N. S., Nelkin, B. D., & Maitra, A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0028 · Cited by 65
Rudolph, D., Impagnatiello, M. A., Blaukopf, C., Sommer, C., Gerlich, D. W., Roth, M., Tontsch-Grunt, U., Wernitznig, A., Savarese, F., Hofmann, M. H., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221150 · Cited by 64
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
Chilà, R., Basana, A., Lupi, M., Guffanti, F., Gaudio, E., Rinaldi, A., Cascione, L., Restelli, V., Tarantelli, C., Bertoni, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2583 · Cited by 63
Desai, B. M., Villanueva, J., Nguyen, T.-T. K., Lioni, M., Xiao, M., Kong, J., Krepler, C., Vultur, A., Flaherty, K. T., Nathanson, K. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059588 · Cited by 63
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs
Hugle, M., Belz, K., & Fulda, S. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.59 · Cited by 62
Sehdev, V., Katsha, A. M., Ecsedy, J., Zaika, A. I., Belkhiri, A., & El-Rifai, W. M. (2012) · Cancer · doi:10.1002/cncr.27801 · Cited by 62
Kanaji, S., Saito, H., Tsujitani, S., Matsumoto, S., Tatebe, S., Kondo, A., Ozaki, M., Ito, H., & Ikeguchi, M. (2006) · Oncology · doi:10.1159/000093003 · Cited by 62
Bowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61
Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R. K., Issa, I., Chakraborty, A., Matano, A., Zhao, X., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2528 · Cited by 61
Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I. M., Mayer, I. A., Abramson, V. G., Ye, F., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2475 · Cited by 61
Enhanced malignant tumorigenesis in Cdk4 transgenic mice
de Marval, P. L. M., Macias, E., Conti, C. J., & Rodríguez‐Puebla, M. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207309 · Cited by 60
Mahadevan, D., Stejskal, A., Cooke, L. S., Manziello, A., Morales, C., Persky, D. O., Fisher, R. I., Miller, T. P., & Qi, W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2413 · Cited by 60
Ellis, P. M., Leighl, N. B., Hirsh, V., Reaume, M. N., Blais, N., Wierzbicki, R. F., Sadrolhefazi, B., Gu, Y., Liu, D., Pilz, K., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.05.010 · Cited by 60
Dai, Y., Chen, S., Kmieciak, M., Zhou, L., Lin, H., Pei, X., & Grant, S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0902 · Cited by 60
Cirstea, D. D., Hideshima, T., Santo, L., Eda, H., Mishima, Y., Nemani, N., Hu, Y., Mimura, N., Cottini, F., Görgün, G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.194 · Cited by 59
Kelly, K. R., Nawrocki, S. T., Espitia, C. M., Zhang, M., Yang, J. J., Padmanabhan, S., Ecsedy, J., Giles, F. J., & Carew, J. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27579 · Cited by 58
Gorlick, R. G., Kolb, E. A., Keir, S. T., Maris, J. M., Reynolds, C. P., Kang, M. H., Carol, H., Lock, R. B., Billups, C. A., Kurmasheva, R. T., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24616 · Cited by 57
Bush, T. L., Payton, M. N., Heller, S., Chung, G., Hanestad, K., Rottman, J. B., Loberg, R. D., Friberg, G. R., Kendall, R. L., Saffran, D. C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1178 · Cited by 57
Schenk, E. L., Koh, B. D., Flatten, K. S., Peterson, K. L., Parry, D., Hess, A. D., Smith, B. D., Karp, J. E., Karnitz, L. M., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0961 · Cited by 57
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo
Niida, H., Murata, K., Shimada, M., Ogawa, K., Ohta, K., Suzuki, K., Fujigaki, H., Khaw, A. K., Banerjee, B., Hande, M. P., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.218 · Cited by 56
Yamamoto, H., Ochiya, T., Takeshita, F., Toriyama‐Baba, H., Hirai, K., Sasaki, H., Sasaki, H., Sakamoto, H., Yoshida, T., Saito, I., et al. (2002) · PubMed · Cited by 56
Squires, M. S., Cooke, L. S., Lock, V., Qi, W., Lewis, E. J., Thompson, N. T., Lyons, J. F., & Mahadevan, D. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1071 · Cited by 56
Cyclin D2 and p27 Are Tissue-Specific Regulators of Tumorigenesis in Inhibin α Knockout Mice
Burns, K. H., Agno, J. E., Siciński, P., & Matzuk, M. M. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0038 · Cited by 53
Weisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., Nelson, E. A., Cowens, K. B., Christie, A. L., Mitsiades, C. S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.149 · Cited by 53
Eilers, G., Czaplinski, J. T., Mayeda, M., Bahri, N., Tao, D. L., Zhu, M. J., Hornick, J. L., Lindeman, N. I., Sicińska, E., Wagner, A. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0793 · Cited by 53
Wang, X., Sinn, A. L., Pollok, K. E., Sandusky, G. E., Zhang, S., Chen, L., Liang, J., Crean, C., Suvannasankha, A., Abonour, R., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08248.x · Cited by 49
Fischler, T., Li, Y., Wang, R.-H., Kim, H.-S., Sengupta, K., Vassilopoulos, A., Lahusen, T. J., Xu, X., Lee, M.-H., Liu, Q., et al. (2010) · Oncogene · doi:10.1038/onc.2010.163 · Cited by 49
Lanasa, M. C., Andritsos, L. A., Brown, J. R., Gabrilove, J. L., Caligaris‐Cappio, F., Ghia, P., Larson, R. A., Kipps, T. J., Leblond, V., Milligan, D. W., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.02.001 · Cited by 48
Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis
Tho, L. M., Libertini, S., Rampling, R., Sansom, O. J., & Gillespie, D. A. (2011) · Oncogene · doi:10.1038/onc.2011.326 · Cited by 48
Gopalan, P. K., Pinder, M. C., Chiappori, A., Ivey, A. M., Gordillo Villegas, A., & Kaye, F. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8077 · Cited by 47
Matulonis, U. A., Lee, J., Lasonde, B., Tew, W. P., Yehwalashet, A., Matei, D. E., Behbakht, K., Grothusen, J., Fleming, G. F., Lee, N. K., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.020 · Cited by 46
Sicinska, E., Lee, Y.-M., Gits, J., Shigematsu, H., Yu, Q., Rebel, V. I., Geng, Y., Marshall, C. J., Akashi, K., Dorfman, D. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-06 · Cited by 45
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma
Ciznadija, D., Liu, Y., Pyonteck, S. M., Holland, E. C., & Koff, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1031 · Cited by 44
MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
Gillam, M. P., Nimbalkar, D., Sun, L., Christov, K. T., Ray, D., Kaldis, P., Liu, X., & Kiyokawa, H. (2014) · Oncogene · doi:10.1038/onc.2014.3 · Cited by 44
Tentler, J. J., Bradshaw‐Pierce, E. L., Serkova, N. J., Hasebroock, K. M., Pitts, T. M., Diamond, J. R., Fletcher, G. C., Bray, M. R., & Eckhardt, S. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0325 · Cited by 44
Cdk2-Null Mice Are Resistant to ErbB-2-Induced Mammary Tumorigenesis
Ray, D., Terao, Y., Christov, K. T., Kaldis, P., & Kiyokawa, H. (2011) · Neoplasia · doi:10.1593/neo.101704 · Cited by 43
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.534 · Cited by 42
Gorlick, R. G., Kolb, E. A., Houghton, P. J., Morton, C. L., Neale, G. A. M., Keir, S. T., Carol, H., Lock, R. B., Phelps, D. A., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24073 · Cited by 40
Mice with the CHEK2 *1100delC SNP are predisposed to cancer with a strong gender bias
Bahassi, E. M., Robbins, S. B., Yin, M., Boivin, G. P., Kuiper, R., STEEG, H. V., & Stambrook, P. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909237106 · Cited by 38
Vassilopoulos, A., Tominaga, Y., Kim, H.-S., Lahusen, T. J., Li, B., Yu, H., Gius, D. R., & Deng, C.-X. (2014) · Oncogene · doi:10.1038/onc.2014.239 · Cited by 37
Degrassi, A., Russo, M., Nanni, C., Patton, V., Alzani, R., Giusti, A. M., Fanti, S., Ciomei, M., Pesenti, E. A., & Texidó, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0726 · Cited by 37
Spartà, A., Bressanin, D., Chiarini, F., Lonetti, A., Cappellini, A., Evangelisti, C., Evangelisti, C., Melchionda, F., Pession, A., Bertaina, A., et al. (2014) · Cell Cycle · doi:10.4161/cc.29267 · Cited by 36
Cdk2 and Cdk4 Activities Are Dispensable for Tumorigenesis Caused by the Loss of p53
Padmakumar, V. C., Aleem, E. A., Berthet, C., Hilton, M. B., & Kaldis, P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00952-08 · Cited by 36
Wang, G., Niu, X., Zhang, W., Caldwell, J. T., Edwards, H. J., Chen, W., Taub, J. W., Zhao, L., & Ge, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.015 · Cited by 35
Torchia, E. C., Chen, Y., Sheng, H., Katayama, H. G., Fitzpatrick, J. A. J., Brinkley, W. R., Caulín, C., Sen, S., & Roop, D. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1059 · Cited by 35
Oza, A. M., Weberpals, J. I., Provencher, D. M., Grischke, E., Hall, M., Uyar, D. S., Estevez-Diz, M. D. P., Marmé, F., Kuzmin, A., Rosenberg, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5506 · Cited by 35
Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer
Duan, W., Gao, L., Aguila, B., Kalvala, A., Otterson, G. A., & Villalona-Calero, M. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00368 · Cited by 33
Smith, A. P. L., Henze, M., Lee, J. A., Osborn, K. G., Keck, J. M., Tedesco, D., Bortner, D. M., Rosenberg, M. P., & Reed, S. I. (2006) · Oncogene · doi:10.1038/sj.onc.1209713 · Cited by 32
Wu, C., Hsieh, C., Hsiao, S.-H., Luo, S.-Y., Su, C.-Y., Li, Y., Huang, Y.-H., Huang, C., & Hsu, S.-C. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00312 · Cited by 31
Loss of p27Kip1 cooperates with cyclin E in T-cell lymphomagenesis
Geisen, C., Karsunky, H., Yücel, R., & Möröy, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206340 · Cited by 30
Rosenthal, A. C., Kumar, S. K., Hofmeister, C. C., Laubach, J. P., Vij, R., Dueck, A. C., Gano, K., & Stewart, A. K. (2015) · British Journal of Haematology · doi:10.1111/bjh.13765 · Cited by 30
Pirkmaier, A., Dow, R., Ganiatsas, S., Waring, P., Warren, K., Thompson, A., Hendley, J., & Germain, D. (2003) · Oncogene · doi:10.1038/sj.onc.1206488 · Cited by 29
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
Tolaney, S. M., Beeram, M., Beck, J. T., Conlin, A. K., Dees, E. C., Dickler, M. N., Helsten, T. L., Conkling, P., Edenfield, W. J., Richards, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.522 · Cited by 29
Macias, E., Kim, Y., de Marval, P. L. M., Klein–Szanto, A. J., & Rodríguez‐Puebla, M. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2119 · Cited by 28
Liu, Y., Hawkins, O. E., Vilgelm, A. E., Pawlikowski, J. S., Ecsedy, J., Sosman, J. A., Kelley, M. C., & Richmond, A. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0293 · Cited by 28
Nemoto, A., Saida, S., Kato, I., Kikuchi, J., Furukawa, Y., Maeda, Y., Akahane, K., Oshiro, H., Goi, K., Kagami, K., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1065 · Cited by 28
Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8026 · Cited by 27
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
Davis, S. L., Robertson, K. M., Pitts, T. M., Tentler, J. J., Bradshaw‐Pierce, E. L., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Selby, H. M., Spreafico, A., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00120 · Cited by 26
The cancer drug that almost wasn't
Garber, K. (2014) · Science · doi:10.1126/science.345.6199.865 · Cited by 25
Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis
Rojas, P. A., Cadenas, M. B., Lin, P.-C., Benavides, F. J., Conti, C. J., & Rodríguez‐Puebla, M. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209970 · Cited by 24
Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
Münster, P. N., Hamilton, E. P., García‐Estévez, L., Boer, R. H. D., Mayer, I. A., Campone, M., Asano, S., Bhansali, S. G., Zhang, V. Y., Hewes, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.26_suppl.143 · Cited by 24
Albanese, C., Alzani, R., Amboldi, N., Degrassi, A., Festuccia, C., Fiorentini, F., Gravina, G. L., Mercurio, C., Pastori, W., Brasca, M. G., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12112 · Cited by 23
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
Lu, Y., Yong-sheng, W., Feng, X., Shen, R. Z., Wang, J. H., Fallahi, M., Li, W., Yang, C., Hankey, W., Zhao, W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci63139 · Cited by 23
Bardia, A., Modi, S., Gregor, M. C.-M., Kittaneh, M., Marino, A. J., Matano, A., Bhansali, S. G., Hewes, B., & Cortés, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.535 · Cited by 23
Macias, E., de Marval, P. L. M., Senderowicz, A. M., Cullen, J. M., & Rodríguez‐Puebla, M. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2461 · Cited by 19
Reddy, H. K. D. L., Graña, X., Dhanasekaran, D. N., Litvin, J., & Reddy, E. P. (2010) · Genes & Cancer · doi:10.1177/1947601909358105 · Cited by 18
Ghamrasni, S. E., Pamidi, A., Halaby, M. J., Bohgaki, M., Cardoso, R., Li, L., Venkatesan, S., Sethu, S., Hirao, A., Mak, T. W., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001385 · Cited by 18
Mammary Tumorigenesis following Transgenic Expression of a Dominant Negative CHK2 Mutant
Kwak, E. L., Kim, S., Zhang, J., Cardiff, R. D., Schmidt, E. V., & Haber, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1237 · Cited by 18
A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.
Clark, A. S., O'Dwyer, P. J., Heitjan, D. F., Lal, P., Feldman, M. D., Gallagher, M., Redlinger, C., Colameco, C., Lewis, D., Zafman, K. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.527 · Cited by 17
Wang, X., Sistrunk, C., & Rodríguez‐Puebla, M. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.032 · Cited by 16
Mu, K., Li, L., Yang, Q., Zhang, T., Gao, P., Meng, B., Liu, Z., Wang, Y., & Zhou, G. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03780.x · Cited by 13
Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
Tolaney, S. M., Hilton, J. F., Cleary, J. M., Gandhi, L., Kwak, E. L., Clark, J. W., Wolanski, A., Bell, T. D., Rodig, S. J., Chiao, J. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2503 · Cited by 11
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Metadata
- Authors
- Otto, T., & Sicinski, P.
- Venue
- Nature Reviews Cancer
- Published
- 2017-01-27
- Volume
- 17
- Issue
- 2
- Pages
- 93-115
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2581841075
- Cited by
- 1,858
- References
- 288
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.